Femasys Directors Report Stock Option Grants in 11 Insider Filings

What happened

Femasys Inc. (NASDAQ: FEMY), a Suwanee, Georgia-based maker of surgical and medical instruments, saw 11 insider transaction filings with the SEC between late June and August 11, 2026. The filings are all Forms 4, which insiders must file when they buy or sell company stock or receive stock options.

The filing shown is from director Kenneth D. Eichenbaum, dated August 11, 2026. It reports a grant of 880 stock options at an exercise price of $3.67 per share, dated June 24, 2026. The options vest one year from the grant date and expire on June 24, 2036.

The cluster of 11 filings over 14 days, all on Form 4, indicates multiple insiders received similar option grants. The filings do not state why the grants were made, and the source does not say whether any insider sold shares.

On the day of the filings, Femasys stock closed at $2.66, down 1.85% from the previous close of $2.71.

What this means

A Form 4 is the SEC document that corporate insiders—directors, officers, and 10% owners—must file within two business days of any transaction in their company's stock. It is required under Section 16(a) of the Securities Exchange Act of 1934.

The transaction code "A" on the Eichenbaum form means "acquisition"—specifically, a grant of stock options. These are not purchases or sales of shares; they are awards of the right to buy company stock at a set price, here $3.67, which is above the current market price of $2.66.

The options vest one year after the grant date, meaning Eichenbaum must remain a director for that year to exercise them. The exercise price, $3.67, is higher than the current stock price, so the options are currently "underwater"—exercising them now would mean paying more than the shares are worth.

A cluster of Form 4s like this typically signals a scheduled compensation event, such as annual director or employee option grants. The filings do not indicate any sale of shares or any change in the company's financial condition.

The stock's 1.85% decline on the filing date is small and could be unrelated to the insider filings, which often have little market impact. The source does not explain the price move.